TRESADERM solution is versatile in more than one way.
TRESADERM® (thiabendazole, dexamethasone, neomycin sulfate solution)
TRESADERM® (thiabendazole, dexamethasone, neomycin sulfate solution) aids in the treatment of certain bacterial, mycotic, and inflammatory dermatoses, and otitis externa in canines and felines.
TRESADERM® (thiabendazole, dexamethasone, neomycin sulfate solution) is a triple-action dermatologic solution that helps treat otitis externa, as well as various localized skin conditions such as ringworm, hot spots, pyoderma, and flea allergy dermatitis. It is effective against opportunistic/concurrent pathogens that may complicate already established mycotic skin disorders or ear mite (Otodectes cynotis) infections.
Thiabendazole, an anti-fungal agent, has significant activity against important dermatophytes such as Microsporum and Trichophyton.
Dexamethasone, an anti-inflammatory agent (synthetic adrenocorticosteroid), inhibits the reaction of connective tissue to injury and suppresses the classic inflammatory manifestations of skin disease.
Neomycin sulfate, an anti-bacterial agent, is effective against both gram-negative and gram-positive bacteria.
Available as an easy-to-use dermatologic solution that reduces the potential for clogging in the ear canal or clumping in the fur.
Trusted by veterinarians for more than 40 years.
Safe and effective to use on both dogs and cats.
TRESADERM® (thiabendazole, dexamethasone, neomycin sulfate solution) is available in 7.5 mL and 15 mL bottles.
Prior to the administration of TRESADERM solution, remove the ceruminous, purulent, or foreign materials from the ear canal, as well as the crust which may be associated with dermatoses affecting other parts of the body.
The design of the container nozzle safely allows partial insertion into the ear canal for ease of administration. The amount to apply and the frequency of treatment are dependent upon the severity and extent of the lesions. Five to 15 drops should be instilled in the ear twice daily.
In treating dermatoses affecting locations other than the ear, the surface of the lesions should be well moistened (2 to 4 drops per square inch) with TRESADERM solution twice daily. The volume required will be dependent upon the size of the lesion.
Application of TRESADERM solution should be limited to a period of no longer than 1 week.
Store in a refrigerator 36-46°F (2-8°C).
Precautions: On rare occasions, dogs may be sensitive to neomycin. In these animals, application of the drug will result in erythema of the treated area, which may last 24 to 48 hours. Also, evidence of transient discomfort has been noted in some dogs when the drug was applied to fissured or denuded areas. The expression of pain may last 2 to 5 minutes.
Application of TRESADERM® (thiabendazole, dexamethasone, neomycin sulfate solution) should be limited to periods not longer than 1 week.
While systemic side effects are not likely with topically applied corticosteroids, such a possibility should be considered if use of the solution is extensive and prolonged. If signs of salt and water retention or potassium excretion are noticed (increased thirst, weakness, lethargy, oliguria, gastrointestinal disturbances, or tachycardia), treatment should be discontinued and appropriate measures taken to correct the electrolyte and fluid imbalance.
WARNING: For topical use in dogs and cats. Avoid contact with eyes.
Keep this and all drugs out of the reach of children.
For more information, please see full prescribing information.
The triple-action treatment of TRESADERM solution allows you to stock one single, effective, and easy-to-administer solution for a variety of ear and skin conditions for both canines and felines.
TRESADERM solution allows you to consolidate your inventory by offering a broad-spectrum solution to your clients.
TRESADERM solution won’t clog the ears or clump the fur of your canine patients, helping ensure a smooth application process.
TRESADERM® is a registered trademark of Boehringer Ingelheim Animal Health USA Inc. All other trademarks are the property of their respective owner.
US-PET-0565-2020-A-V2